CADTH Canadian Drug Expert Review Committee final recommendation : indication: pulmonary arterial hypertension. Riociguat (Adempas - Bayer HealthCare Inc.)

MLA

Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Review Committee final recommendation : indication: pulmonary arterial hypertension. Riociguat (Adempas - Bayer HealthCare Inc.). Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015.

APA

Canadian Agency for Drugs and Technologies in Health. (2015). CADTH Canadian Drug Expert Review Committee final recommendation : indication: pulmonary arterial hypertension. Riociguat (Adempas - Bayer HealthCare Inc.). Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health.

Chicago

Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Review Committee final recommendation : indication: pulmonary arterial hypertension. Riociguat (Adempas - Bayer HealthCare Inc.). Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015.